Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 236 participants.
Also called NCT03597412
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 236 participants
- Sponsor
- Registry
-
NCT03597412
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03597412. Randomized; no masking; primary purpose treatment. Start 2018-10-17 (actual); primary completion 2020-08-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rosuvastatin/Ezetimibe Versus Rosuvastatin in ASCVD Patients With Type 2 DM
- Acronym
- MIRA
- Condition
- Atherosclerotic Cardiovascular Disease
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Rosuvamibe
- Intervention (Drug)
- Monorova
- Lead sponsor
- Yuhan Corporation
Record details
- Record id
cardio:ct-nct03597412- Content hash
024a9ba1e715b28c166276dddc04a6f929ef8fa900a46ba26cedd8958f3a9f5c